A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster Portfolio News / By Libby Nunan A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster Read More »
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer Portfolio News / By Libby Nunan Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer Read More »
Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer Portfolio News / By Libby Nunan Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer Read More »
Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors Portfolio News / By Libby Nunan Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors Read More »
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering Portfolio News / By Libby Nunan Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering Read More »
GSK enters agreement to acquire RAPT Therapeutics Portfolio News / By Libby Nunan GSK enters agreement to acquire RAPT Therapeutics Read More »
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones Read More »
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Portfolio News / By Libby Nunan Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Read More »
A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression Portfolio News / By Libby Nunan A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression Read More »
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform Portfolio News / By Libby Nunan InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform Read More »
